KUOW 94.9, Nov. 13, 2017
There was a time when the cure for leukemia was almost as lethal as the disease. Before bone marrow transplants, patients were treated with arsenic or radiation — and the outlook was often considered hopeless.
GeekWire, Oct. 26, 2017
Biotech journalist Luke Timmerman spends most of his time reading and writing about medical innovation. But now, he’s doing a lot more: Literally climbing Mount Everest to raise awareness, and cash, for cancer research.
Timmerman teamed up with Fred Hutchinson Cancer Research Center to organize a campaign in conjunction with the Climb to Fight Cancer, which launched Thursday. The goal is to raise $175,000 for Fred Hutch’s cancer research efforts before he hits the trail March 27, 2018.
KOMO News, Oct. 27, 2017
Get a glimpse of Luke Timmerman carrying a backpack up and down the Howe Street Stairs in Seattle and you might guess that he’s a mountain climber in training. You’d be correct.
Back in his office a few blocks away, he shows off the photos that prove it.
“So I always try to find that moment when the sunrise is just coming over the horizon,” said Timmerman.
In one photo, the sun peaks above the summit of Aconcagua, one of the World’s seven summits.
Front Line Genomics, July. 25, 2017
Welcome to The Short Read, our weekly peek behind the curtain at the people who make this amazing community tick. Make sure to check back every Tuesday for the latest installment.
Luke Timmerman is an award-winning journalist who has focused on biotechnology for more than a decade. He is the founder and editor of Timmerman Report, a biotech newsletter. Prior to this, he covered biotechnology at The Seattle Times, Xconomy, and Bloomberg News. He was also named one of the 100 most influential people in biotech in 2015 by Scientific American.
WBUR 90.9 FM, July. 10, 2017
It’s been a relatively slow year for the U.S. biotech sector. So far, only 16 companies nationwide have gone public since January.
That’s about half as many as during the boom years between 2013 and 2015.
But the last couple of weeks have seen four IPOs, including two here in Massachusetts, for the firms Mersana and Aileron. Both are focused on cancer drugs.
For a look at the dry spell, and what might be driving the possible shift underway, we spoke to Luke Timmerman, founder and editor of the biotech industry newsletter the Timmerman Report.
Nieman Lab, Jan. 9, 2017
When it comes to running your own one-person media company, the hardest problems are often the smallest.
In 2015, veteran biotech reporter Luke Timmerman set out on his own to launch The Timmerman Report, a $149-a-year subscription product offering original news and analysis about the biotech industry. The product quickly found its audience: Within ten months, Timmerman had attracted 1,000 subscribers, which he says was evidence that the idea could work in the long term. (Timmerman hasn’t shared an updated subscriber number publicly since.)
The Seattle Times, Dec. 17, 2016
Seattle Genetics hides its big ambitions in a modest-looking set of beige Bothell office-park buildings, while some of its cousins in the local biotech world crowd together in the brainy-hood of Seattle’s South Lake Union. But there is nothing modest about this 18-year-old company, which is plowing forward patiently and aims to make a major splash in the cancer-drug market in 2017.
Poynter, Apr. 11, 2016
Luke Timmerman was about to place a very big bet on himself.
Slightly more than a year ago, the veteran reporter quit his job at a startup and decided to go into business for himself. The business, as it had been for more than a decade, was journalism. But this time, he was the boss. And there was no one else on staff.
CBS News, Dec. 17, 2015
For many social media users, Martin Shkreli’s arrest Thursday on charges of securities fraud is cause for holiday cheer. Tweets featuring Shkreli’s “perp walk” — wearing a grey hoodie and his hands cuffed behind his back — proliferated, as well as comments such as the one from actress Debra Messing’s succinct “Karmas a bitch” and others giving thanks for an early holiday gift.
Forbes, Nov. 2, 2015
Last week executives at both Pfizer and Allergan acknowledged that they have begun merger talks. Pfizer’s PFE goal in such a move is pretty simple – to finally achieve the tax-saving corporate inversion it has been seeking for some time.
Talking Biz News, Oct. 21, 2015
Luke Timmerman is the founder and editor of The Timmerman Report, an online website covering the biotechnology industry for $99 a year. Before starting his own publication nine months ago, Timmerman was national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News.
MIT Biotechnology Group, Sep. 25, 2015
Being well informed is critical to keeping your edge in the biotech space. Too many trainees keep their nose to the grindstone and don’t see what’s happening in the news (which, for those working in Kendall, is typically happening right across the street). It doesn’t take too much effort to stay up to date, but finding quality sources in the first place can be difficult. So close your Facebook tab, let your PCR go a few more cycles, and get informed for a few minutes every day.
Scientific American Worldview, June 24, 2015
At just 40 years old, biotechnology is a relatively new industry. Its starting point, arguably, was the 1975 Asilomar Conference on Recombinant DNA, at which the potential benefits and hazards of DNA manipulation and the ways it should be regulated were debated and essentially decided upon.
Forbes, Feb. 7, 2015
Last summer, at a time when many traditional publications were downsizing their health footprint, Politico made the bold decision to invest deeply in this area, and hired three strong healthcare journalists (Arthur Allen, Ashley Gold, and David Pittman) to staff a newly-launched eHealth PoliticoPro vertical, increasing the size of the Politico health team to eleven* – two editors and nine* reporters.
MedCityNews, Feb. 3, 2015
Luke Timmerman’s gone rogue.
The veteran life sciences reporter, who left Xconomy last year, is back to day-to-day journalism. Except this time, he’s doing it on his own: Timmerman just launched his own biotech site – The Timmerman Report – with plans to charge readers a modest sum to gain access to his insights.
Mendelspod podcast, Feb. 3, 2015
Just less than a year ago, the national biotech editor at Xconomy, Luke Timmerman, left his post. Yeah, he just left it. Gone was the regular Monday column that helped us all absorb the newest trends in biotech. Gone were the lists of companies to watch out for that made sense even if we weren’t up to date on Luke’s sports analogies.
MIT Knight Science Journalism Fellowships blog, Feb. 3, 2015
It’s a daring career move, considering that some freelancing for Forbes and a book-in-progress about systems biology pioneer Lee Hood are his only other gigs. But Timmerman says he thinks he thinks he can make it work as his main source of income. And as a longtime marathon runner and mountain climber, he’s certainly no stranger to situations that call for endurance.
Geekwire, Feb. 2, 2015
Luke Timmerman, a respected biotechnology journalist known for his past work at The Seattle Times and Xconomy, today launched a new subscription-based biotech news site, The Timmerman Report.